Additionally, the prevalence of certain gene mutations, including TERTp (62%), CDKN2A (60%), TP53 (13%), ARID2 (10%), and PTEN (10%), within melanomas with active RAF1 fusions can aid in refining tumor classification strategies [12]. This evidence concerns the gene CDKN2A and melanoma.